Eventide Gilead N
Willow Grove, PA19090
630-a Fitzwatertown Road 2nd Floor
Mutual Fund Series Trust
866-447-4228
管理資訊
,自 2008年7月7日 起的牽頭經辦人
Finny Kuruvilla, MD, PhD, serves as a Co-Chief Investment Officer, Senior Portfolio Manager for Eventide’s mid-cap growth and healthcare & life sciences strategies, a Managing Director for Eventide’s private fund, as well as Founding Member of Eventide.
Dr. Kuruvilla has a background in healthcare, statistics, and investing. Concurrent with his early years at Eventide, he was a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm subsequently acquired by Blackstone. Earlier in his career, Dr. Kuruvilla was a postdoctoral research fellow at the Broad Institute of Harvard and MIT, where he led the development of a new microarray between the Broad Institute and a publicly-traded company Affymetrix. Prior to his investing career, Dr. Kuruvilla was resident, chief resident, and fellow at the Brigham and Women’s Hospital and Boston Children’s Hospital.
Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a SM in Electrical Engineering and Computer Science from MIT, and a BS in Chemistry from Caltech.
晨星風格箱
Yahoo 與領先的市場研究和投資數據集團晨星合作，幫助投資者評分和比較 Yahoo 財經上的基金。晨星類別是根據基金的相關證券而識別基金的投資焦點，並會顥示在晨星風格箱旁邊。
晨星類別
雖然基金招股書所述的投資目標可能會或不會反映實際的基金投資狀況，但晨星類別會根據每個投資組合中的相關證券作分配。晨星類別幫助投資者和投資專業人士作出有意義的基金比較。這些類別讓投資者更容易建立多樣化的投資組合、評估潛在風險，並找出表現最好的基金。我們根據過去三年的投資組合統計數據和成分將基金歸類。如果沒有過往投資組合的新成立的基金，我們在分配一個永久類別前，會先預測該基金的類別。必要時，我們可能會根據投資組合最新的變化來更改類別分配。
基金總覽
類別Mid-Cap Growth
基金家族Eventide Funds
淨資產3.25十億
本年度至今日回報-0.44%
收益率0.00%
晨星評級★★
成立日期2009年10月27日
基金運作
上次股息0.03
上次資本增益29.00
持股週轉率36.00%
組別平均無
費用與支出
支出ETGLX類別平均
年報支出比率 (淨值)1.38%1.09%
招股書淨支出比率1.38%無
招股書總支出比率1.38%無
最高 12b1 費用無無
最高首次認購費無5.36%
最高遞延銷售費用無1.27%
3 年支出預測0無
5 年支出預測0無
10 年支出預測0無
